San Diego biotechnology company Autobahn Therapeutics on Wednesday said it raised $100 million to advance an experimental mood disorder medicine into mid-stage testing.
The company, which launched in 2020, is developing the drug for major depressive disorder and bipolar disorder depression.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,